Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents

Area of Science:

• Oncology
• Nephrology
• Cardiology

Background:

• Vascular endothelial growth factor inhibitors (VEGF-Is) are key treatments for metastatic renal cell carcinoma (mRCC).
• Hypertension is a frequent and significant side effect of VEGF-Is, impacting treatment adherence and outcomes.
• The precise mechanisms underlying VEGF-I-induced hypertension are not fully elucidated.

Purpose of the Study:

• To establish expert-based guiding principles for the diagnosis and management of hypertension in mRCC patients receiving VEGF-Is.
• To provide a consensus framework in the absence of randomized clinical trial data.

Main Methods:

• A consensus process involving Canadian medical oncologists and hypertension specialists.
• Review of Canadian Hypertension Education Program guidelines and existing literature.
• Incorporation of expert opinion to formulate management strategies.

Main Results:

• The guiding principles address the diagnosis and management of VEGF-I-induced hypertension.
• Recommendations are based on a synthesis of current guidelines, literature, and expert consensus.
• The principles aim to standardize care for this common side effect.

Conclusions:

• VEGF-Is have transformed mRCC treatment, but hypertension management requires clear guidance.
• Expert consensus provides a practical framework for managing VEGF-I-induced hypertension in mRCC patients.
• Standardized management of hypertension can optimize treatment outcomes for mRCC patients receiving VEGF-Is.